Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (81-90 of 437) with videos related to

Pageof 44
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimenMartin Reck, Gesine Groth, Erika Buchholz, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of lightChristoph Jakob Ackermann, Martin Reck, Luis Paz-Ares, et al.
Lung Cancer (Amsterdam, Netherlands)|June 11, 2011
Tissue sampling in lung cancer: a review in light of the MERIT experienceMartin Reck, Andreas Hermes, Eng-Huat Tan, et al.
Lancet (London, England)|August 27, 2013
Management of non-small-cell lung cancer: recent developmentsMartin Reck, David F Heigener, Tony Mok, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2020
Combination of Immunotherapy and Radiotherapy-The Next Magic Step in the Management of Lung Cancer?Lizza E L Hendriks, Jessica Menis, Dirk K M De Ruysscher, et al.
Clinical Lung Cancer|June 28, 2006
Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancerMartin Reck, Erika Buchholz, Kathrin Schott-von Romer, et al.
Onkologie|June 13, 2009
[Response judgement - conventional versus new methods]Stefan Diederich, Peter Engeser, Klaus Junker, et al.
Cancer Biomarkers : Section a of Disease Markers|July 24, 2012
Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLCGeorge R Blumenschein, Martin Reck, Frank Fossella, et al.
Romanian Journal of Morphology and Embryology = Revue Roumaine De Morphologie Et Embryologie|March 21, 2018
Preselection of EGFR mutations in non-small-cell lung cancer patients by immunohistochemistry: comparison with DNA-sequencing, EGFR wild-type expression, gene copy number gain and clinicopathological dataRania Gaber, Iris Watermann, Christian Kugler, et al.
Anticancer Research|October 28, 2015
Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?Wolfram C M Dempke, Klaus Edvardsen, Shun Lu, et al.
Pageof 44

Showing results (81-90 of 437) with videos related to

Sort By:
Pageof 44
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimenMartin Reck, Gesine Groth, Erika Buchholz, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of lightChristoph Jakob Ackermann, Martin Reck, Luis Paz-Ares, et al.
Lung Cancer (Amsterdam, Netherlands)|June 11, 2011
Tissue sampling in lung cancer: a review in light of the MERIT experienceMartin Reck, Andreas Hermes, Eng-Huat Tan, et al.
Lancet (London, England)|August 27, 2013
Management of non-small-cell lung cancer: recent developmentsMartin Reck, David F Heigener, Tony Mok, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2020
Combination of Immunotherapy and Radiotherapy-The Next Magic Step in the Management of Lung Cancer?Lizza E L Hendriks, Jessica Menis, Dirk K M De Ruysscher, et al.
Clinical Lung Cancer|June 28, 2006
Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancerMartin Reck, Erika Buchholz, Kathrin Schott-von Romer, et al.
Onkologie|June 13, 2009
[Response judgement - conventional versus new methods]Stefan Diederich, Peter Engeser, Klaus Junker, et al.
Cancer Biomarkers : Section a of Disease Markers|July 24, 2012
Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLCGeorge R Blumenschein, Martin Reck, Frank Fossella, et al.
Romanian Journal of Morphology and Embryology = Revue Roumaine De Morphologie Et Embryologie|March 21, 2018
Preselection of EGFR mutations in non-small-cell lung cancer patients by immunohistochemistry: comparison with DNA-sequencing, EGFR wild-type expression, gene copy number gain and clinicopathological dataRania Gaber, Iris Watermann, Christian Kugler, et al.
Anticancer Research|October 28, 2015
Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?Wolfram C M Dempke, Klaus Edvardsen, Shun Lu, et al.
Pageof 44